Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Danny Almaguer

Podiatrist, Primary Podiatric Medicine Eagle Pass, TX Doctor of Podiatric Medicine

NPI 1104982925 CMS profile 907087

2525 N Veterans Blvd, Eagle Pass, TX 78852

Open in the dashboard

General payments

$615

39 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Danny Almaguer of Eagle Pass, TX is reported in the CMS Open Payments database as having received $615 across 39 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 50th percentile of Podiatrist, Primary Podiatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $177 9
2024 General $195 14
2023 General $110 7
2022 General $92 6
2021 General $28 2
2019 General $14 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Danny Almaguer
  • Podiatrist, Primary Podiatric Medicine median
  • Middle half of Podiatrist, Primary Podiatric Medicine
  • National median

In program year 2025, general payments to Danny Almaguer were reported at $177. Among 368 Podiatrist, Primary Podiatric Medicine profiles paid that year, the median was $232 and the middle half received between $88 and $586.

Show as a table
Year Danny Almaguer Podiatrist, Primary Podiatric Medicine median Middle half National median
2019 $14 $166 $51–$513 $163
2020 $0 $108 $33–$249 $114
2021 $28 $147 $52–$377 $132
2022 $92 $188 $66–$551 $149
2023 $110 $195 $70–$509 $160
2024 $195 $209 $59–$508 $164
2025 $177 $232 $88–$586 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $509 32 payments
  2. Janssen Pharmaceuticals, Inc $20 1 payment
  3. Merck Sharp & Dohme Corporation $17 1 payment
  4. Dexcom, Inc. $14 1 payment
  5. Amgen Inc. $14 1 payment
  6. GlaxoSmithKline, LLC. $14 1 payment
  7. Otsuka America Pharmaceutical, Inc. $14 1 payment
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $615 39 payments
Products named General payments · program years 2019–2025
  1. Ozempic $146 10 payments
  2. RYBELSUS $132 9 payments
  3. XARELTO $20 1 payment
  4. GARDASIL 9 $17 1 payment
  5. CAPVAXIVE $17 1 payment
  6. ROTATEQ $17 1 payment
  7. VAXNEUVANCE $17 1 payment
  8. VAXELIS $17 1 payment
  9. Dexcom G6 Transmitter $14 1 payment
  10. Otezla $14 1 payment
  11. Other $68 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

1,297

Median for Podiatry: 160

Drug cost

$34,506

Median for Podiatry: $2,368

Branded share of claims

38.7%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Ciclopirox Olamine Brand 469 $18,197
Clotrimazole Generic 627 $9,998
Ciclopirox Generic 101 $4,164
Econazole Nitrate Generic 28 $1,102
Diclofenac Sodium Generic 15 $441
Ssd Silver Sulfadiazine Brand 33 $257
Ketoconazole Generic 13 $254
Gabapentin Generic 11 $94

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $14
$14 — —
Otezla
  • Amgen Inc. $7
$7 — —
Repatha
  • Amgen Inc. $7
$7 — —
SHINGRIX
  • GlaxoSmithKline, LLC. $7
$7 — —
AREXVY
  • GlaxoSmithKline, LLC. $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

39 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Primary Podiatric Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record